Automation in cell and gene therapy manufacturing promises lower costs, improved efficiency, and expanded access to life-saving treatments worldwide.

Abeona Therapeutics (ABEO) stock gets a "Buy" rating, driven by ZEVASKYN's commercial launch for RDEB and strong early demand signals. Read the full analysis here.

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete ...

New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th ...

The technology is designed to simplify the bio-separation process while reducing manufacturing costs.

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Abeona's Zevaskyn provides a runway to potential profitability at the price of $3.1 million per treatment. Read my analysis ...

For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an ...